3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
42
Rectal Neoplasms
31
Colorectal Neoplasms
31
Pancreatic Neoplasms
30
Neoplasms
26
Stomach Neoplasms
20
Neoplasm Metastasis
17
Colonic Neoplasms
13
Unspecified Adult Solid Tumor, Protocol Specific
12
Esophageal Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Solid Tumor
7
Biliary Tract Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Liver Neoplasms
4
Carcinoma, Hepatocellular
4
Bile Duct Neoplasms
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Melanoma
3
Head and Neck Neoplasms
3
Gallbladder Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Ovarian Epithelial
3
Appendiceal Neoplasms
3
Anus Neoplasms
3
Adenocarcinoma
3
Vaginal Neoplasms
2
Uterine Cervical Neoplasms
2
Interventions
Photochemotherapy
4
1-phenyl-3,3-dimethyltriazene
4
sonidegib
2
pembrolizumab
2
HhAntag691
2
Biopsy
2
tozuleristide
1
tocilizumab
1
talimogene laherparepvec
1
silmitasertib
1
prednylidene
1
poly ICLC
1
flt3 ligand protein
1
deltacortene
1
cemiplimab
1
Tacrolimus
1
TAK-441
1
Sirolimus
1
SUB1 protein, human
1
Radiotherapy
1
Radiation
1
Prednisone
1
Nivolumab
1
NVP-LEQ506
1
Microarray Analysis
1
Mass Spectrometry
1
Laser Therapy
1
Ipilimumab
1
Imiquimod
1
Glatiramer Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Basal Cell
×
Capecitabine
×
Clear all
NCT03775525
2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1
Unknown
127 enrolled